392 related articles for article (PubMed ID: 17877812)
1. Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs.
Hayase T
BMC Neurosci; 2007 Sep; 8():76. PubMed ID: 17877812
[TBL] [Abstract][Full Text] [Related]
2. Nicotine (NC)-induced "depressive" behavioral symptoms and effects of antidepressants including cannabinoids (CBs).
Hayase T
J Toxicol Sci; 2008 Dec; 33(5):555-64. PubMed ID: 19043277
[TBL] [Abstract][Full Text] [Related]
3. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
4. Working memory- and anxiety-related behavioral effects of repeated nicotine as a stressor: the role of cannabinoid receptors.
Hayase T
BMC Neurosci; 2013 Feb; 14():20. PubMed ID: 23394117
[TBL] [Abstract][Full Text] [Related]
5. Anxiolytic effects of yokukansan, a traditional Japanese medicine, via serotonin 5-HT1A receptors on anxiety-related behaviors in rats experienced aversive stress.
Yamaguchi T; Tsujimatsu A; Kumamoto H; Izumi T; Ohmura Y; Yoshida T; Yoshioka M
J Ethnopharmacol; 2012 Sep; 143(2):533-9. PubMed ID: 22819689
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.
Patel S; Hillard CJ
J Pharmacol Exp Ther; 2006 Jul; 318(1):304-11. PubMed ID: 16569753
[TBL] [Abstract][Full Text] [Related]
7. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors.
Urigüen L; Pérez-Rial S; Ledent C; Palomo T; Manzanares J
Neuropharmacology; 2004 Jun; 46(7):966-73. PubMed ID: 15081793
[TBL] [Abstract][Full Text] [Related]
8. Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?
Consoli D; Leggio GM; Mazzola C; Micale V; Drago F
Eur J Pharmacol; 2007 Nov; 573(1-3):139-47. PubMed ID: 17669397
[TBL] [Abstract][Full Text] [Related]
9. Reversal by quercetin of corticotrophin releasing factor induced anxiety- and depression-like effect in mice.
Bhutada P; Mundhada Y; Bansod K; Ubgade A; Quazi M; Umathe S; Mundhada D
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):955-60. PubMed ID: 20447436
[TBL] [Abstract][Full Text] [Related]
10. The benzodiazepine diazepam demonstrates the usefulness of Syrian hamsters as a model for anxiety testing: evaluation of other classes of anxiolytics in comparison to diazepam.
Gannon RL; Lungwitz E; Batista N; Hester I; Huntley C; Peacock A; Delagrange P; Millan MJ
Behav Brain Res; 2011 Mar; 218(1):8-14. PubMed ID: 21094664
[TBL] [Abstract][Full Text] [Related]
11. WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent.
Hughes ZA; Liu F; Platt BJ; Dwyer JM; Pulicicchio CM; Zhang G; Schechter LE; Rosenzweig-Lipson S; Day M
Neuropharmacology; 2008 Jun; 54(7):1136-42. PubMed ID: 18423777
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors.
Hayase T
BMC Pharmacol; 2011 Jul; 11():6. PubMed ID: 21767384
[TBL] [Abstract][Full Text] [Related]
13. Prenatal cocaine and/or nicotine exposure produces depression and anxiety in aging rats.
Sobrian SK; Marr L; Ressman K
Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):501-18. PubMed ID: 12691787
[TBL] [Abstract][Full Text] [Related]
14. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression.
Wesołowska A; Nikiforuk A; Stachowicz K; Tatarczyńska E
Neuropharmacology; 2006 Sep; 51(3):578-86. PubMed ID: 16828124
[TBL] [Abstract][Full Text] [Related]
15. Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety models: interaction with drugs acting at 5-HT receptors.
Peng WH; Wu CR; Chen CS; Chen CF; Leu ZC; Hsieh MT
Life Sci; 2004 Oct; 75(20):2451-62. PubMed ID: 15350820
[TBL] [Abstract][Full Text] [Related]
16. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor.
Chaki S; Hirota S; Funakoshi T; Suzuki Y; Suetake S; Okubo T; Ishii T; Nakazato A; Okuyama S
J Pharmacol Exp Ther; 2003 Feb; 304(2):818-26. PubMed ID: 12538838
[TBL] [Abstract][Full Text] [Related]
17. Putative Epigenetic Involvement of the Endocannabinoid System in Anxiety- and Depression-Related Behaviors Caused by Nicotine as a Stressor.
Hayase T
PLoS One; 2016; 11(7):e0158950. PubMed ID: 27404492
[TBL] [Abstract][Full Text] [Related]
18. Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon.
Rajarao SJ; Platt B; Sukoff SJ; Lin Q; Bender CN; Nieuwenhuijsen BW; Ring RH; Schechter LE; Rosenzweig-Lipson S; Beyer CE
Neuropeptides; 2007 Oct; 41(5):307-20. PubMed ID: 17637475
[TBL] [Abstract][Full Text] [Related]
19. Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice.
Biala G; Kruk M
J Pharm Pharmacol; 2009 Apr; 61(4):493-502. PubMed ID: 19298697
[TBL] [Abstract][Full Text] [Related]
20. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression.
Bespalov AY; van Gaalen MM; Sukhotina IA; Wicke K; Mezler M; Schoemaker H; Gross G
Eur J Pharmacol; 2008 Sep; 592(1-3):96-102. PubMed ID: 18634781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
